PMID- 36013165
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230317
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 16
DP  - 2022 Aug 22
TI  - Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with 
      Advanced-Stage Plasmablastoid Large B-Cell Lymphoma.
LID - 10.3390/jcm11164928 [doi]
LID - 4928
AB  - Plasmablastic lymphoma (PBL) is a rare and aggressive form of large B-cell 
      lymphoma (LBCL) most commonly seen in the setting of chronic immunosuppression or 
      autoimmune disease. The prognosis is poor and CHOP-like regimens often fail to 
      produce durable remission; therefore, there is no established standard of care 
      treatment. However, PBL demonstrates substantial morphologic and immunophenotypic 
      overlap with multiple myeloma (MM), suggesting that MM therapeutics might prove 
      useful in treating PBL. We studied the effects of treatment using the 
      first-in-class monoclonal antibody directed against CD38, daratumumab, in 
      combination with chemotherapy in seven patients with advanced-stage LBCL with 
      plasmablastic features. Treatment was safe and well-tolerated. Among six 
      evaluable patients, six patients had complete response after treatment, and four 
      patients who met strict WHO criteria for PBL had durable response (12-31 months 
      and ongoing).
FAU - Ryu, Yun Kyoung
AU  - Ryu YK
AUID- ORCID: 0000-0002-8745-0906
AD  - Division of Hematology-Oncology, Department of Medicine, Columbia University 
      Irving Medical Center, New York, NY 10032, USA.
FAU - Ricker, Edd C
AU  - Ricker EC
AD  - Columbia University Vagelos College of Physicians and Surgeons, New York, NY 
      10032, USA.
FAU - Soderquist, Craig R
AU  - Soderquist CR
AD  - Department of Pathology, Columbia University Irving Medical Center, New York, NY 
      10032, USA.
FAU - Francescone, Mark A
AU  - Francescone MA
AD  - Department of Radiology, Columbia University Irving Medical Center, New York, NY 
      10032, USA.
FAU - Lipsky, Andrew H
AU  - Lipsky AH
AD  - Division of Hematology-Oncology, Department of Medicine, Columbia University 
      Irving Medical Center, New York, NY 10032, USA.
FAU - Amengual, Jennifer E
AU  - Amengual JE
AUID- ORCID: 0000-0003-4117-2469
AD  - Division of Hematology-Oncology, Department of Medicine, Columbia University 
      Irving Medical Center, New York, NY 10032, USA.
LA  - eng
GR  - UL1 TR001873/TR/NCATS NIH HHS/United States
GR  - The Esther and Oded Aboodi Lymphoma Research Fund (JEA)/
PT  - Journal Article
DEP - 20220822
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC9409851
OTO - NOTNLM
OT  - anti-CD38
OT  - daratumumab
OT  - lymphoma
OT  - plasmablastoid
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/27 06:01
PMCR- 2022/08/22
CRDT- 2022/08/26 01:28
PHST- 2022/07/16 00:00 [received]
PHST- 2022/08/14 00:00 [revised]
PHST- 2022/08/16 00:00 [accepted]
PHST- 2022/08/26 01:28 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/27 06:01 [medline]
PHST- 2022/08/22 00:00 [pmc-release]
AID - jcm11164928 [pii]
AID - jcm-11-04928 [pii]
AID - 10.3390/jcm11164928 [doi]
PST - epublish
SO  - J Clin Med. 2022 Aug 22;11(16):4928. doi: 10.3390/jcm11164928.